TITLE

PFIZER'S EPIDEMIC: A NEED FOR INTERNATIONAL REGULATION OF HUMAN EXPERIMENTATION IN DEVELOPING COUNTRIES

AUTHOR(S)
Carr, David M.
PUB. DATE
January 2003
SOURCE
Case Western Reserve Journal of International Law;Winter2003, Vol. 35 Issue 1, p15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Explores the need for international regulation of human experimentation (HE) in developing countries. Legal background behind current international standards concerning HE; Details behind the events that took place in Nigeria between Pfizer and the Nigerian families involved in a lawsuit; Analysis of voluntary consent and enforcement under current international standards.
ACCESSION #
13466314

 

Related Articles

  • At Your Own RISK. Lemonick, Michael D.; Goldstein, Andrew; Park, Alice // Time International (South Pacific Edition);4/22/2002, Issue 15, p46 

    Focuses on the risks associated with clinical trials in medicine. Debate about the safety regulations of the trials, which often involve desperately ill patients; Expectation that the number of trials will increase, and along with that, the number of deaths; Description of various scandals such...

  • The evolution of standards for experimental treatment or research. Slovenko, Ralph // Journal of Psychiatry & Law;Spring2005, Vol. 33 Issue 1, p129 

    Discusses the historical evolution of standards for experimental treatment or research involving human subjects. Key reason for the creation of standards; Debates on the universal standards for justifying human experiments at the Nuremberg tribunal; Basis of the U.S. Supreme Court in supporting...

  • Self experimentation and the Nuremberg Code: Ethics review is needed only when other people are subjects too. Annas, George J. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/18/2010, Vol. 341 Issue 7786, p1279 

    The author comments on the suggested exception of self experimentation in article 5 of the Nuremberg Code in medicine. He asserts that this exception has never been persuasive and there is no experiment that should be done if there is an a priori reason to believe that death or injury will occur...

  • The Problem with Optimism in Clinical Trials. Jansen, Lynn A. // IRB: Ethics & Human Research;Jul/Aug2006, Vol. 28 Issue 4, p13 

    The author reflects on the phenomenon of "unrealistic optimism" in clinical research compromising informed consent. She argues that its implications for the ethics of clinical research have not been fully appreciated and the phenomenon may be more difficult to address than either the therapeutic...

  • Personal reflections on lessons learned from randomized trials involving newborn infants from 1951 to 1967. Silverman, William A. // Clinical Trials;2004, Vol. 1 Issue 2, p179 

    The article discusses personal reflections on lessons learned from randomized trials involving newborn infants from 1951 to 1967. This essay is being reprinted from the James Lind Library, a wonderful online cornucopia of historical information created to introduce people to the characteristics...

  • Issues in Human Experimentation. Gordon Jr., Robert S. // Annals of Internal Medicine;Nov78 Part 2, Vol. 89 Issue 5, p846 

    Discusses issues that arise when human beings participate in experiments. Issue on confidentiality of preliminary results of clinical studies; Issue on compensation for research-related injuries.

  • Human Subjects Research: HHS Takes Steps to Strengthen Protections, But Concerns Remain: GAO-01-775T.  // GAO Reports;5/23/2001, p1 

    At the federal level the Department of Health and Human Services (HHS) is seeking to better protect human subjects in biomedical research by enhancing the visibility of its human subjects protection activities, improving its monitoring of compliance with relevant regulations by institutions and...

  • No delayed disclosure for registration of clinical trials. Fleck, Fiona // Bulletin of the World Health Organization;Jun2006, Vol. 84 Issue 6, p430 

    The article reports that the World Health Organization has introduced disclosure rules for pharmaceutical companies and research institutions to make clinical trials more transparent and publicly accountable. They will have to submit 20 key details when they register clinical trials with human...

  • Science Atrocities. Cottle, Thomas J. // New Republic;9/13/75, Vol. 173 Issue 11, p5 

    Comments on the revelation that the U.S. government is conducting LSD drug experiments on people. Large scale experimentation with LSD; Importance of not telling the subjects of the nature of the experiment for fear that the experiment's results would be prejudiced; Author's view that these...

Share

Read the Article

Other Topics